NCPA submitted comments to CMS on its draft pharmacy agreements as part of the Medicare Drug Price Negotiation Program of the Inflation Reduction Act.
NCPA stressed that the agreements were not fair to pharmacies given that, among other things, CMS is proposing that pharmacies be required to join them as a condition for participation in Medicare Part D generally; that CMS is disclaiming all warranties and protections to pharmacies; that the audit and notice requirements for termination are overly burdensome on pharmacies; and that CMS can unilaterally modify these contracts.
For NCPA talking points on the MDPN Program, see here.
NCPA
